References
- World Health Organisation–International Society of Hypertension. Guidelines for the management of hypertension. J Hypertens 1999;17:151–83
- Marquez-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the ‘rule of halves’ still valid? J Hum Hypertens 1997;11:213–20
- Buhler FR. The role of calcium channel blockers as first-line treatment of hypertension. J Hypertens 1992;10:17–20
- Schmieder RE, Martus P, Klingbeil D. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. J Am Med Assoc 1996;275:1507–13
- Taddei S, Virdis A, Ghiadoni L, Uleri S, Magagna A, Salvetti A. Lacidipine restores endothelium-dependent vasodilatation in essential hypertensive patients. Hypertension 1997;30: 1606–12
- Schiffrin E, Deng LY. Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonist. J Hypertens 1995;14:1247–55
- Zanchetti A, Rosei EA, Dal Palu C, Leonetti G, Magnani B, Pessina A. The Verapamil in hypertension and atherosclerosis study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998;16:1667–76
- Freedman DD, Waters DD. Second generation dihydropyridine calcium antagonist. Greater vascular selectivity and some unique applications. Drugs 1987;34:578–98
- Hollemberg NK. Hypertension and the kidney: determinants of the response to antihypertensive therapy and their implications. Am Hearth J 1993;125:604–8
- Scholz H. Pharmacological aspects of calcium channel blockers. Cardiovasc Drugs Ther 1997;10:869–72
- Rosenthal J. Nilvaldipine: profile of a new calcium antagonist, an overview. J Cardiovasc Pharmacol 1994;24\(Suppl. 2):S92–S107
- Von Niecicki A, Huber HJ, Stanislaus F. Pharmacokinetics of nilvadipine. J Cardiovasc Pharmacol 1992;20\(Suppl. 6):S22–S29
- Frison L, Pocock SJ. Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med 1992;11:1685–704
- Brogden RN, McTavish D. Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina. Drugs Aging 1995;6(2):150–71
- Keck M. Comparison of the efficacy of nilvadipine and nitrendipine on circadian blood pressure. J Cardiovasc Pharmacol 1992;20(Suppl 6):S43–S49
- Faust G. A one year study of single administration of nilvadipine. Results of the effectiveness and long-term tolerance in hypertension. Fortschr Med 1993;111(11):188–92
- Faust G. The tolerability of nilvadipine compared to nifedipine in patients with essential hypertension. J Cardiovasc Pharmacol 1992;20(Suppl 6):S56–S61
- Oparil S. Long-term morbidity and mortality trials with amlodipine. J Cardiovasc Pharmacol 1999;33(Suppl 2):S1–S6
- Nayler WG. Review of preclinical data of calcium channel blockers and atherosclerosis. J Cardiovasc Pharmacol 1999;33(Suppl 2): S7–S11
- Turgan N, Habif S, Kabaroglu CG, Mutaf I, Ozmen D, Bayindir O, Uysal A. Effects of the calcium channel blocker amlodipine on serum and aortic cholesterol, lipid peroxidation, antioxidant status and aortic histology in cholesterol-fed rabbits. J Biomed Sci 2003;10(1):65–72
- Tulenko TN, Brown J, Laury-Kleintop L, Khan M, Walter MF, Mason RP. Atheroprotection with amlodipine: cells to lesions and the PREVENT trial. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial. J Cardiovasc Pharmacol 1999;33(Suppl 2):S17–S22